Literature DB >> 2888150

The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness.

R Miller.   

Abstract

In neuroleptic therapy for psychotic illness, clinical improvement is produced more slowly than is central dopamine blockade, and its time course is highly variable between patients. A theory of neuroleptic-responsive psychotic illness thus requires more than dopamine blockade, though that appears to be the first step in the therapeutic process. Some previous explanations given for the protracted time course of neuroleptic therapy are discussed, with emphasis on the hypothesis of delayed inactivation of midbrain dopamine neurones. For various reasons all explanations are unsatisfactory. An alternative hypothesis is proposed in which neuroleptic-responsive psychoses are seen as arising from a hyperactivity of the associations of thought. Such psychoses thus involve a disorder of a high-level learning process, namely the elaboration of memories of thoughts and beliefs. Neuroleptic drugs are envisaged to remedy this process, but not to eradicate the abnormal memories already formed. Psychotic symptoms may thus outlast the start of neuroleptic therapy by many weeks. It is suggested that the pharmacological characteristics of the hypothetical learning process involved in generating psychotic symptoms are analogous to those of a simpler learning process, defineable in animal experiments - namely, the reward component in instrumental conditioning. A preliminary case is made that the relative potency of different neuroleptic drugs in antipsychotic therapy can better be predicted by their relative potency in retarding such a variety of learning, than by other behavioural tests of these drugs.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888150     DOI: 10.1007/bf00176470

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  87 in total

1.  Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect?

Authors:  B Costall; R J Naylor
Journal:  Psychopharmacologia       Date:  1973

Review 2.  The psychoses of epilepsy and their treatment.

Authors:  M R Trimble
Journal:  Clin Neuropharmacol       Date:  1985       Impact factor: 1.592

3.  Neuroleptics and brain self-stimulation behavior.

Authors:  A Wauquier
Journal:  Int Rev Neurobiol       Date:  1979       Impact factor: 3.230

4.  Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity.

Authors:  B Scatton; S Bischoff; J Dedek; J Korf
Journal:  Eur J Pharmacol       Date:  1977-08-15       Impact factor: 4.432

5.  Enhanced noradrenergic neuronal activity increases homovanillic acid levels in cerebrospinal fluid.

Authors:  H Scheinin
Journal:  J Neurochem       Date:  1986-09       Impact factor: 5.372

6.  Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia.

Authors:  J G Knight
Journal:  Lancet       Date:  1982-11-13       Impact factor: 79.321

7.  A double-blind outpatient study of diazepam (Valium) and placebo.

Authors:  R Gundlach; D M Engelhardt; L Hankoff; H Paley; L Rudorfer; E Bird
Journal:  Psychopharmacologia       Date:  1966

8.  Pimozide-induced extinction in rats: stimulus control of responding rules out motor deficit.

Authors:  K B Franklin; S N McCoy
Journal:  Pharmacol Biochem Behav       Date:  1979-07       Impact factor: 3.533

9.  Pimozide and amphetamine have opposing effects on the reward summation function.

Authors:  C R Gallistel; D Karras
Journal:  Pharmacol Biochem Behav       Date:  1984-01       Impact factor: 3.533

10.  Major psychosis and dopamine: controversial features and some suggestions.

Authors:  R Miller
Journal:  Psychol Med       Date:  1984-11       Impact factor: 7.723

View more
  6 in total

Review 1.  How antipsychotics work-from receptors to reality.

Authors:  Shitij Kapur; Ofer Agid; Romina Mizrahi; Ming Li
Journal:  NeuroRx       Date:  2006-01

2.  Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: further test of the motivational salience hypothesis.

Authors:  Min Feng; Nan Sui; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2012-09-28       Impact factor: 3.533

3.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

4.  An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-03       Impact factor: 2.293

Review 5.  Neuroleptics and psychic indifference: a review.

Authors:  D Healy
Journal:  J R Soc Med       Date:  1989-10       Impact factor: 18.000

6.  "Getting physical": the management of neuropsychiatric disorders using novel physical treatments.

Authors:  Gin S Malhi; Colleen Loo; Catherine M Cahill; Jim Lagopoulos; Philip Mitchell; Perminder Sachdev
Journal:  Neuropsychiatr Dis Treat       Date:  2006-06       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.